首頁
InvaGen Pharmaceuticals

7月 2026InvaGen Pharmaceuticals的市場佔有率分析

built on the foundation of caring for life, cipla ensures access to quality & affordable medicines through 1500+ products across various therapeutic categories.

行業: N/A

域名invagen.com

成立年份2003

僱員501 - 1000

年度營收$200M - $500M

InvaGen Pharmaceuticals

InvaGen Pharmaceuticals（包含公司地區）

invagen.com

查看更多網站流量與參與度資訊

InvaGen Pharmaceuticals截至 7月 2026 的總收入為 200M - 500M

InvaGen Pharmaceuticals 熱門網域產生的總收入

InvaGen Pharmaceuticals 熱門網域 3 年內的總收入

InvaGen Pharmaceuticals 熱門網域的總收入

invagen.com200M - 500M

透過銷售情報查看更多內容

InvaGen Pharmaceuticals的熱門網域總造訪量

了解InvaGen Pharmaceuticals市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

InvaGen Pharmaceuticals的熱門網域平均造訪時長

分析InvaGen Pharmaceuticals參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

InvaGen Pharmaceuticals的熱門網域平均頁面瀏覽量

了解InvaGen Pharmaceuticals如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

InvaGen Pharmaceuticals按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術InvaGen Pharmaceuticals

这些是InvaGen Pharmaceuticals顶级域名使用的行业网站技术

內容管理系統 (3)

WordPress

付費廣告 (1)

Awin

轉換與分析 (1)

Google Analytics

電子郵件服務 (1)

G Suite

更多技術

4

檢視所有

新聞與訊號來自InvaGen Pharmaceuticals

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Cipla acquired Invagen for $550M on Jan 1st '15.Cipla entered the US market in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015.

新聞Invagen invests into assets: product under development and related assets in the amount of $12.5M.Pharma major Cipla ‘ s subsidiary InvaGen Pharmaceuticals Inc is acquiring US-based specialty business firm Avenue Therapeutics for up to $215 million while Aurobindo Pharma Ltd agreed to buy a product under development and related assets from Australia-based Advent Pharmaceuticals Pty. Ltd for $12.5 million in an all-cash deal.

新聞Invagen acquired Avenue Therapeutics for $215M on Nov 1st '18.New Delhi, Nov 13 () Drug major Cipla Tuesday said its subsidiary InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to USD 215 million (around Rs 1,560 crore).